Advertisement

Biological Trace Element Research

, Volume 187, Issue 2, pp 472–481 | Cite as

Therapeutic Effect of Strontium Ranelate on Bone in Chemotherapy-Induced Osteopenic Rats via Increased Bone Volume and Reduced Bone Loss

  • Yi Pei
  • Ke Zheng
  • GuanNing Shang
  • YuMing Wang
  • Wei Wang
  • EnDuo Qiu
  • ShenLong Li
  • XiaoJing ZhangEmail author
Article
  • 107 Downloads

Abstract

The purpose of this study was to determine whether treatment with strontium ranelate (SrR) can restore bone mass and strength at a skeletal site with established osteopenia in chemotherapy-induced rats. Forty-five Sprague-Dawley male rats were randomly assigned to three study groups (n = 15 rats per group): normal rats (control group), osteopenic rats (chemo group), and osteopenic rats with SrR (chemo-SrR group). We chose a male rat model that mimicked a clinical setting by weekly intravenous injection of cyclophosphamide at 20 mg/kg. The control and chemo groups were maintained without treatment, and the chemo-SrR group was intragastrically administered strontium ranelate at a dosage of 900 mg/kg/day. All animals were fed a standard laboratory diet, and blood samples were collected for biochemical analysis. After 12 weeks of treatment, micro-CT, biomechanical testing, and histomorphometry were examined. In addition, bone samples were obtained to evaluate the content of mineral substances in bones. SrR treatment of chemo rats significantly increased tibial trabecular bone volume, trabecular thickness, and BV/TV. Serum levels of the bone formation marker alkaline phosphatase (ALP) in the SrR group were significantly higher than those in the chemo animals, which was accompanied by an increase in the bone mineral content, bone calcium and phosphate, as well as reduced serum Ca and P concentrations. The serum level of tartrate-resistant acid phosphatase (TRAP) in the SrR treatment group showed no obvious changes. Histomorphological analyses revealed that chemotherapy resulted in decreased osteoclast number, which may be due to the inhibition of bone turnover. However, SrR treatment enhanced the number of osteoblasts while restoring bone mass and improving bone strength in chemo rats. Therefore, the results of this study indicate that SrR treatment has a positive effect on bone in chemotherapy-induced osteoporosis.

Keywords

Strontium Chemotherapy-induced Osteoporosis Cyclophosphamide Bone volume 

Notes

Compliance with Ethical Standards

All animal procedures were conducted in accordance with the National Institutes of Health guidelines for the use of experimental animals.

References

  1. 1.
    Dupuis LL, Roscoe JA, Olver I, Aapro M, Molassiotis A (2017) 2016 updated MASCC/ESMO consensus recommendations: anticipatory nausea and vomiting in children and adults receiving chemotherapy. Support Care Cancer 25:317–321CrossRefGoogle Scholar
  2. 2.
    Body JJ (2010) Prevention and treatment of side-effects of systemic treatment: bone loss. Ann Oncol 21(Suppl 7):vii180–vii185PubMedGoogle Scholar
  3. 3.
    Hines SL, Mincey BA, Sloan JA, Thomas SP, Chottiner E, Loprinzi CL, Carlson MD, Atherton PJ, Salim M, Perez EA (2009) Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol 27:1047–1053CrossRefGoogle Scholar
  4. 4.
    Nielsen SP (2004) Review the biological role of strontium. Bone 35(3):583–588CrossRefGoogle Scholar
  5. 5.
    E. Bonnelye, A. Chabadel, F. Saltel, P. Jurdic (2008) Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone 42129–138, 42, 129Google Scholar
  6. 6.
    Meunier PJ, Roux C, Ortolani S et al (2009) Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporosis International 20(10):1663–1673CrossRefGoogle Scholar
  7. 7.
    Tenti S, Cheleschi S, Guidelli GM, Galeazzi M, Fioravanti A (2014) What about strontium ranelate in osteoarthritis? Doubts and securities. Mod Rheumatol 24(6):881–884CrossRefGoogle Scholar
  8. 8.
    Reginster JY, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R, Brandi ML, Spector TD, Brixen K, Goemaere S, Cormier C, Balogh A, Delmas PD, Meunier PJ (2008) Effects of long-term strontium ranelate treatment on the risk of non-vertebral and vertebral fractures in postmenopausal osteoporosis: results of a 5-year, randomized, placebo-controlled trial. Arthritis Rheum 58:1687–1695CrossRefGoogle Scholar
  9. 9.
    Reginster JY, Brandi ML, Cannata-Andía J, Cooper C, Cortet B, Feron JM, Genant H, Palacios S, Ringe JD, Rizzoli R (2015) The position of strontium ranelate in today’s management of osteoporosis. Osteoporos Int 26:1667–1671CrossRefGoogle Scholar
  10. 10.
    Qi W, Yan Y-b, Wang P-j, Lei W (2011) The co-effect of Cordyceps sinensis and strontium on osteoporosis in ovariectomized osteopenic rats. Biol Trace Elem Res 141:216–223CrossRefGoogle Scholar
  11. 11.
    Qin D-w, Gu Z, Dai L, Ji C (2013) Protective effects of gallium, germanium, and strontium against ovariectomized osteoporosis in rats. Biol Trace Elem Res 153:350–354CrossRefGoogle Scholar
  12. 12.
    Li Z, Peng S, Pan H, Tang B, Lam RWM, Lu WW (2012) Microarchitecture and nanomechanical properties of trabecular bone after strontium administration in osteoporotic goats. Biol Trace Elem Res 145:39–46CrossRefGoogle Scholar
  13. 13.
    Moulin M, Piquereau J, Mateo P, Fortin D, Rucker-Martin C, Gressette M, Lefebvre F, Gresikova M, Solgadi A, Veksler V, Garnier A, Ventura-Clapier R (2015) Sexual dimorphism of doxorubicin-mediated cardiotoxicity: potential role of energy metabolism remodeling. Circ Heart Fail 8(1):98–108CrossRefGoogle Scholar
  14. 14.
    Sato M, Shiozawa K, Uesugi T, Hiromatsu R, Fukuda M, Kitaura K, Minami T, Matsumoto S (2009) Collaborative work on evaluation of ovarian toxicity. 7 Effects of 2- or 4- week repeated dose studies and fertility study of cyclophosphamide in female rats. J Toxicol Sci 34(Suppl 1):SP83–89Google Scholar
  15. 15.
    Stevenson M, Davis S, Lloyd-Jones M, Beverley C (2007) The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women. Health Technol Assess 11(4):1–134CrossRefGoogle Scholar
  16. 16.
    Ammann P, Shen V, Robin B, Mauras Y, Bonjour JP, Rizzoli R (2004) Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J Bone Miner Res 19:2012–2020CrossRefGoogle Scholar
  17. 17.
    Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468CrossRefGoogle Scholar
  18. 18.
    Verhulp E, van Rietbergen B, Huiskes R (2004) A three-dimensional digital image correlation technique for strain measurements in microstructures. J Biomech 37:1313–1320CrossRefGoogle Scholar
  19. 19.
    Pei Y, Fu Q (2011) The effects of vanadium (V) absorbed by Coprinus comatus on bone in streptozotocin-induced diabetic rats. Biol Trace Elem Res 142:748–759CrossRefGoogle Scholar
  20. 20.
    Curtis EM, Moon RJ, Dennison EM, Harvey NC, Cooper C (2015) Recent advances in the pathogenesis and treatment of osteoporosis. Clin Med 15(6):S92–S96CrossRefGoogle Scholar
  21. 21.
    Hassett MJ, O’Malley AJ, Pakes JR, Newhouse JP, Earle CC (2006) Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 98(16):1108–1117CrossRefGoogle Scholar
  22. 22.
    Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson IC, Citron ML, Norton L, Winer EP, Hudis CA (2007) Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol 25(24):3699–3704CrossRefGoogle Scholar
  23. 23.
    Testa NG, Hendry JH, Molineux G (1985) Long-term bone marrow damage in experimental systems and in patients after radiation or chemotherapy. Anticancer Res 5(1):101–110Google Scholar
  24. 24.
    Kang MJ, Lim JS (2013) Bone mineral density deficits in childhood cancer survivors: pathophysiology, prevalence, screening, and management. Korean J Pediatr 56:60–67CrossRefGoogle Scholar
  25. 25.
    Schwartz A, Leonidas J (1984) Methotrexate osteopathy. Skeletal Radiol 11:13–16CrossRefGoogle Scholar
  26. 26.
    Wangenheim KH, Peterson HP, Cronkite EP, Feinendegen LE (1987) 5-Fluorouracil treatment after irradiation impairs recovery of bone marrow functions. Radiat Environ Biophys 26:163–170CrossRefGoogle Scholar
  27. 27.
    Cegieła U, Piatek A, Janiec W et al (2003) Effect of cyclophosphamide on bone remodeling in rats. PrzeglLek 60:329–333Google Scholar
  28. 28.
    Coleman RE, Rathbone E, Brown JE (2013) Management of cancer treatment-induced bone loss. Nat Rev Rheumatol 9(6):365–374CrossRefGoogle Scholar
  29. 29.
    Brennan TC, Rybchyn MS, Green W, Atwa S, Conigrave AD, Mason RS (2009) Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br J Pharmacol 157(7):1291–1300CrossRefGoogle Scholar
  30. 30.
    Kyllönen L, D'Este M, Alini M, Eglin D (2015) Local drug delivery for enhancing fracture healing in osteoporotic bone. Acta Biomater:11412–11434Google Scholar
  31. 31.
    Kaufman JM, Audran M, Bianchi G, Braga V, Diaz-Curiel M, Francis RM, Goemaere S, Josse R, Palacios S, Ringe JD, Felsenberg D, Boonen SJ (2013) Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. Clin.Endocrinol Metab 98:592–601CrossRefGoogle Scholar
  32. 32.
    Meunier PJ, Roux C, Ortolani S, Diaz-Curiel M, Compston J, Marquis P, Cormier C, Isaia G, Badurski J, Wark JD, Collette J, Reginster JY (2009) Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int:201663–201673Google Scholar
  33. 33.
    Fan C, Georgiou KR, McKinnon RA, Keefe DM, Howe PR, Xian CJ (2016) Combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil causes trabecular bone loss, bone marrow cell depletion and marrow adiposity in female rats. J Bone Miner Metab 34(3):277–290CrossRefGoogle Scholar
  34. 34.
    Georgiou KR, Hui SK, Xian CJ (2012) Regulatory pathways associated with bone loss and bone marrow adiposity caused by aging, chemotherapy, glucocorticoid therapy and radiotherapy. Am J Stem Cells 1:205–224PubMedPubMedCentralGoogle Scholar
  35. 35.
    Georgiou KR, King TJ, Scherer MA, Zhou H, Foster BK, Xian CJ (2012) Attenuated Wnt/b-catenin signalling mediates methotrexate chemotherapy-induced bone loss and marrow adiposity in rats. Bone 50:1223–1233CrossRefGoogle Scholar
  36. 36.
    Błogowski W, Ratajczak MZ, Zyzniewska-Banaszak E, Doł egowska B, Starzy’nska T (2012) Adipose tissue as a potential source of hematopoietic stem/progenitor cells. Obesity 20:923–931CrossRefGoogle Scholar
  37. 37.
    Peng S, Liu XS, Wang T, Li Z, Zhou G, Luk KD, Guo XE, Lu WW (2010) In vivo anabolic effect of strontium on trabecular bone was associated with increased osteoblastogenesis of bone marrow stromal cells. J Orthop Res 28(9):1208–1214CrossRefGoogle Scholar
  38. 38.
    Fournier C, Perrier A, Thomas M, Laroche N, Dumas V, Rattner A, Vico L, Guiqnandon A (2012) Reduction by strontium of the bone marrow adiposity in mice and repression of the adipogenic commitment of multipotent C3H10T1/2 cells. Bone 50:499–509CrossRefGoogle Scholar
  39. 39.
    Bakker AD, Zandieh-Doulabi B, Klein-Nulend J (2013) Strontium ranelate affects signaling from mechanically-stimulated osteocytes towards osteoclasts and osteoblasts. Bone 53(1):112–119CrossRefGoogle Scholar
  40. 40.
    Kaufman JM, Audran M, Bianchi G, Braga V, Diaz-Curiel M, Francis RM, Goemaere S, Josse R, Palacios S, Ringe JD, Felsenberg D, Boonen SJ (2013) Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab 98(2):592–601CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Bone and Soft Tissue Surgery, Liaoning Cancer Hospital & InstituteCancer Hospital of China Medical UniversityShenyangPeople’s Republic of China

Personalised recommendations